Abstract:In order to evaluate the potential and mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone)nanoparticles (ANG-PEG-NP) as brain targeting drug delivery system, Rhodamine B isothiocyanate (RBITC) was used as a fluorescent probe molecule to label ANG-PEG-NP through covalent bonding. The brain transcytosis across the blood-brain barrier (BBB) and brain delivery in mice of RBITC labeled ANG-PEG-NP were investigated in this paper. Results showed that ANG-PEG-NP enhanced significantly the uptake by BCECs compared with that of PEG-NP through caveolae- and clathrin-mediated endocytosis, involving a time-dependent, concentration-dependent and energy-dependent mode. The transport of ANG-PEG-NP across the in vitro BBB model was significantly increased than that of PEG-NP. After injection a dose of 100 mg/kg RBITC labeled ANG-PEG-NP or PEG-NP in mouse caudal vein, the brain coronal section showed a higher accumulation of ANG-PEG-NP in the cortical layer, lateral ventricle, third ventricles and hippocampus than that of PEG-NP. By using an excess of free LRP ligand (Angiopep-2 and/or Aprotinin) as a specific receptor inhibitor, it was evidenced that the uptake by BCECs in vitro, transport across in vitro BBB model and penetration into brain tissue in vivo of RBITC labeled ANG-PEG-NP could be inhibited significantly, which demonstrated the brain targeting mechanism of Angiopep-conjugated poly(ethylene glycol)-co-poly(ε-caprolactone)nanoparticles might be a LRP receptor mediated transcytosis process. Understanding these issues is important for the future development of ANG-PEG-NP as a brain targeting drug delivery system for neurodegenerative disorders including glioma and Alzheimer's disease.

Identification of Peptide Sequences That Target to the Brain Using in Vivo Phage Display

In vivo phage display screen for peptide sequences that cross the blood–cerebrospinal-fluid barrier

Targeting The Brain With Peg-Plga Nanoparticles Modified With Phage-Displayed Peptides

Phage-Displayed Peptide-Conjugated Biodegradable Nanoparticles Enhanced Brain Drug Delivery

Virus-Derived Peptides for Clinical Applications

Novel Blood–Brain Barrier Shuttle Peptides Discovered through the Phage Display Method

Crossing the blood-brain-barrier with nanoligand drug carriers self-assembled from a phage display peptide

Application of the phage display technology for the development of peptide-mediated drug delivery systems through the blood-brain barrier.

In vivo phage display: identification of organ-specific peptides using deep sequencing and differential profiling across tissues

Peptide Phage Display as a Tool for Drug Discovery: Targeting Membrane Receptors

Tumor-Targeting Peptides Search Strategy for the Delivery of Therapeutic and Diagnostic Molecules to Tumor Cells

Molecular determinants for brain targeting by peptides: a meta-analysis approach with experimental validation

In vivo phage display identifies novel peptides for cardiac targeting

Gene delivery targeted to the brain using an Angiopep-conjugated polyethyleneglycol-modified polyamidoamine dendrimer.

A Facile Approach to Functionalizing Cell Membrane-Coated Nanoparticles with Neurotoxin-Derived Peptide for Brain-Targeted Drug Delivery.

Sortase-Mediated Peptide Ligation and Cyclization for Phage Display

Efficient LRP1-Mediated Uptake and Low Cytotoxicity of Peptide L57 In Vitro Shows Its Promise as CNS Drug Delivery Vector

The Brain Targeting Mechanism of Angiopep-conjugated Poly(ethylene Glycol)-Co-poly(ɛ-caprolactone) Nanoparticles

Enhanced glioma-targeting and stability of L GICP peptide coupled with stabilized peptide D A7R.

PEGylated Poly(2-(Dimethylamino) Ethyl Methacrylate)/dna Polyplex Micelles Decorated with Phage-Displayed TGN Peptide for Brain-Targeted Gene Delivery.

PHASTpep: Analysis Software for Discovery of Cell-Selective Peptides via Phage Display and Next-Generation Sequencing